Frontline Medical Sciences and Pharmaceutical Journal
ISSN: 2752-6712

Advances in Solid Dispersion Strategies for Solubility Enhancement of BCS Class II Drugs: A Comprehensive Review

Dr. Lokendra Singh Chundawat

Faculty of Pharmacy (Mandsaur University) Mandsaur, M.P. India

ARTICLE INfO

Articlehistory:
Submission Date:25April2026
Accepted Date:30April2026
Published Date:07May2026
VOLUME: Vol.06Issue05
Page No. 32-45

ABSTRACT

The oral route remains the most preferred and widely accepted route of drug administration because of its convenience, patient compliance, and economic advantages. However, the therapeutic effectiveness of numerous active pharmaceutical ingredients is limited by poor aqueous solubility and low dissolution rates. Biopharmaceutics Classification System (BCS) Class II drugs are characterized by high permeability but poor solubility, making dissolution the rate-limiting step in drug absorption. Over the past few decades, solid dispersion technology has emerged as one of the most promising strategies for improving the solubility, dissolution rate, and oral bioavailability of poorly water-soluble drugs. This review comprehensively examines the advances in solid dispersion approaches for BCS Class II drugs, with particular emphasis on formulation strategies, preparation techniques, carrier systems, characterization methods, and industrial applications. The review discusses conventional and advanced solid dispersion systems including eutectic mixtures, amorphous dispersions, solid solutions, glass solutions, lipid-based dispersions, and supersaturating formulations. Various preparation methods such as solvent evaporation, hot-melt extrusion, spray drying, freeze drying, electrospinning, and supercritical fluid technology are critically analyzed. Furthermore, the review highlights the mechanisms responsible for solubility enhancement, including particle size reduction, amorphization, wettability improvement, and inhibition of drug recrystallization. Current challenges related to scale-up, stability, regulatory compliance, and commercialization are discussed alongside future opportunities involving nanotechnology, machine learning-assisted formulation development, and continuous manufacturing.

Keywords: BCS Class II drugs, solid dispersion, solubility enhancement, amorphous solid dispersion, hot-melt extrusion, spray drying, dissolution rate, bioavailability

INTRODUCTION

The development of effective oral pharmaceutical formulations remains one of the primary objectives of modern drug delivery research. Oral administration is universally recognized as the most convenient and patient-friendly route because of ease of administration, improved patient compliance, reduced cost, and flexibility in dosage form design. Despite these advantages, oral bioavailability of many active pharmaceutical ingredients is significantly compromised due to inadequate aqueous solubility. In recent decades, the pharmaceutical industry has increasingly encountered challenges associated with poorly water-soluble compounds, particularly with the advent of combinatorial

chemistry and high-throughput screening techniques that tend to generate highly lipophilic molecules with complex chemical structures [1]. These compounds frequently exhibit low dissolution rates in gastrointestinal fluids, thereby limiting absorption and therapeutic efficacy.

The Biopharmaceutics Classification System (BCS), introduced by Amidon and colleagues, categorizes drugs into four classes based on aqueous solubility and intestinal permeability [2]. BCS Class II drugs possess high permeability but poor aqueous solubility, making dissolution the rate-limiting step in oral absorption. Examples of BCS Class II drugs include itraconazole, ketoconazole, carbamazepine, glibenclamide, ibuprofen, celecoxib, and fenofibrate. Because these compounds can readily permeate biological membranes once dissolved, enhancing their dissolution characteristics becomes a critical strategy for improving bioavailability.

The pharmaceutical consequences of poor solubility are substantial. Low aqueous solubility often results in erratic absorption profiles, delayed onset of action, increased variability in pharmacokinetic performance, and reduced therapeutic outcomes. Furthermore, formulation scientists may be compelled to administer higher doses to compensate for poor bioavailability, thereby increasing the risk of toxicity and adverse effects [3]. These limitations not only affect patient health outcomes but also increase development costs and complicate regulatory approval processes.

To overcome these challenges, numerous solubility enhancement strategies have been developed, including salt formation, micronization, nanocrystal technology, cyclodextrin complexation, lipid-based formulations, co-crystallization, self-emulsifying systems, and solid dispersions [4]. Among these approaches, solid dispersion technology has gained particular attention because of its simplicity, versatility, and remarkable ability to improve dissolution behavior. The concept of solid dispersions was first introduced by Sekiguchi and Obi in 1961, who demonstrated enhanced dissolution of sulfathiazole through eutectic mixtures with water-soluble carriers [5]. Since then, extensive research has transformed solid dispersion systems into sophisticated pharmaceutical platforms capable of addressing diverse formulation challenges.

Solid dispersions generally refer to systems in which one or more active pharmaceutical ingredients are dispersed in an inert carrier matrix in the solid state [6]. The carrier matrix may consist of hydrophilic polymers, surfactants, lipids, sugars, or combinations thereof. Depending on the physicochemical nature of the drug and carrier, solid dispersions may exist in crystalline, amorphous, molecularly dispersed, or glassy forms. The principal mechanisms underlying dissolution enhancement include particle size reduction, improved wettability, increased porosity, reduced crystallinity, and formation of supersaturated states [7].

The increasing importance of solid dispersion technologies can be attributed to several factors. First, approximately 40–70% of newly discovered drug candidates exhibit poor aqueous solubility, making formulation optimization essential for successful commercialization [8]. Second, advances in polymer science and manufacturing technologies have enabled the development of stable amorphous dispersions with improved shelf life and scalability. Third, regulatory agencies have recognized the value of solid dispersion systems in improving therapeutic performance, leading to the successful commercialization of several products including Sporanox®, Kaletra®, and Cesamet® [9].

The scientific basis of solid dispersion systems is closely linked to thermodynamic and kinetic principles governing drug solubilization and crystallization behavior. Crystalline drugs possess highly ordered molecular arrangements associated with low free energy states. Consequently, substantial energy is required to disrupt crystal lattices and facilitate dissolution. Amorphous forms, by contrast, exhibit higher free energy and molecular mobility, leading to enhanced apparent solubility and dissolution rates [10]. However, amorphous systems are inherently unstable and prone to recrystallization during storage. Therefore, formulation scientists must carefully select carrier systems capable of stabilizing the amorphous drug phase and preventing crystallization.

Hydrophilic polymers play a central role in modern solid dispersion formulations. Commonly used carriers include polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), Soluplus®, poloxamers, and copovidone [11]. These polymers improve wettability, inhibit crystallization, and facilitate molecular dispersion of drugs within the carrier matrix. The selection of an appropriate polymer depends on factors such as drug-polymer miscibility, glass transition temperature, hygroscopicity, and processing compatibility.

Preparation methods have evolved considerably since the early development of solid dispersions. Conventional techniques such as fusion and solvent evaporation have been supplemented by advanced technologies including hot-melt extrusion, spray drying, freeze drying, electrospinning, and supercritical fluid processing [12]. Hot-melt extrusion has emerged as one of the most commercially viable approaches because of its solvent-free operation, continuous processing capability, and scalability. Spray drying, on the other hand, offers excellent control over particle morphology and rapid solvent removal. The choice of manufacturing method significantly influences particle characteristics, stability, and dissolution performance.

The role of surfactants in solid dispersion systems has also attracted significant attention. Surfactants such as Tween 80, sodium lauryl sulfate, Cremophor RH40, and poloxamers can enhance solubility by reducing interfacial tension and promoting wetting [13]. In ternary solid dispersions, surfactants may synergistically interact with polymers to improve drug release and stabilize supersaturated solutions. The incorporation of surfactants is particularly beneficial for highly hydrophobic compounds with strong tendencies toward recrystallization.

Despite substantial progress, several challenges continue to limit the broader application of solid dispersion technologies. Physical instability remains one of the most critical concerns because amorphous drugs tend to revert to

thermodynamically stable crystalline forms during storage [14]. Moisture absorption, elevated temperature, and mechanical stress can accelerate recrystallization, thereby compromising dissolution performance. In addition, scale-up and manufacturing reproducibility present significant industrial challenges. Variations in processing conditions may affect drug distribution, particle morphology, and residual solvent levels.

Another important consideration is the selection of suitable characterization techniques for evaluating solid dispersions. Comprehensive characterization is essential for understanding drug-polymer interactions, crystallinity, thermal behavior, and dissolution kinetics. Analytical techniques commonly employed include differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), nuclear magnetic resonance spectroscopy (NMR), and dissolution testing [15]. These methods provide valuable insights into molecular interactions and physical stability.

The growing integration of nanotechnology with solid dispersion systems has opened new opportunities for enhancing drug delivery performance. Nano-solid dispersions combine the advantages of nanoscale particle size with amorphous stabilization, resulting in exceptionally high dissolution rates [16]. Moreover, the incorporation of mesoporous materials, nanofibers, and lipid-based carriers has expanded the versatility of solid dispersion formulations.

Regulatory and quality considerations have also become increasingly important in the development of solid dispersions. Regulatory agencies require comprehensive evaluation of physical stability, residual solvents, impurity profiles, and manufacturing consistency. The application of Quality by Design (QbD) principles has facilitated systematic optimization of formulation variables and process parameters [17]. By identifying critical quality attributes and critical process parameters, pharmaceutical scientists can develop robust formulations with predictable performance.

In recent years, computational modeling and artificial intelligence have begun to influence solid dispersion research. Molecular dynamics simulations, Hansen solubility parameters, and machine learning algorithms are being used to predict drug-polymer miscibility, optimize carrier selection, and forecast stability behavior [18]. These technologies may significantly reduce formulation development time and improve success rates in future pharmaceutical research.

The clinical significance of improving solubility extends beyond pharmacokinetic enhancement. Enhanced dissolution profiles may reduce dose variability, improve therapeutic consistency, and enable patient-centric dosage forms with lower drug loading requirements [19]. Moreover, improved bioavailability can reduce manufacturing costs by decreasing the quantity of active pharmaceutical ingredient required to achieve therapeutic efficacy.

Several marketed formulations demonstrate the practical success of solid dispersion technologies. Sporanox® capsules containing itraconazole utilize hydroxypropyl methylcellulose-based solid dispersions to improve dissolution and absorption [20]. Likewise, Kaletra® employs melt extrusion technology to formulate ritonavir and lopinavir in amorphous dispersions, thereby enhancing oral bioavailability. These examples illustrate the translational potential of solid dispersion research from laboratory investigation to commercial application.

The pharmaceutical industry continues to explore novel excipients and multifunctional polymers for advanced solid dispersion systems. Amphiphilic polymers, enteric carriers, pH-responsive materials, and biodegradable polymers are increasingly investigated for targeted drug delivery applications [21]. Such innovations may enable site-specific release, improved stability, and enhanced therapeutic outcomes.

Environmental and sustainability concerns have also influenced the evolution of solid dispersion manufacturing. Conventional solvent-based techniques may involve toxic organic solvents and high energy consumption. Consequently, greener approaches such as supercritical fluid technology, solvent-free extrusion, and continuous processing are gaining prominence [22]. Sustainable manufacturing practices are expected to play a critical role in future pharmaceutical development.

The literature reveals substantial variability in the performance of different solid dispersion systems depending on drug properties, carrier composition, and processing conditions. Some systems exhibit rapid initial dissolution but poor long-term stability, whereas others demonstrate excellent stability but limited dissolution enhancement. Therefore, a comprehensive understanding of formulation principles and molecular interactions is essential for rational design.

The present review aims to critically analyze recent advances in solid dispersion technologies for enhancing the solubility of BCS Class II drugs. Particular attention is devoted to the classification of solid dispersions, mechanisms of solubility enhancement, carrier selection, manufacturing technologies, characterization methods, stability considerations, and industrial applications. Furthermore, emerging trends involving nanotechnology, continuous manufacturing, and computational modeling are explored to provide insight into future directions in this field.

REVIEW OF LITERATURE

The scientific literature concerning solid dispersion systems has expanded significantly over the last three decades because of the increasing prevalence of poorly water-soluble drug candidates in pharmaceutical pipelines. Early investigations focused primarily on simple eutectic mixtures and fusion-based dispersions, whereas contemporary studies emphasize molecular-level interactions, advanced processing technologies, and long-term physical stability [23]. The literature consistently demonstrates that solid dispersion technology represents one of the most effective approaches for improving the dissolution behavior of BCS Class II compounds.

The foundational work by Sekiguchi and Obi established the conceptual basis for solid dispersions by demonstrating enhanced dissolution of sulfathiazole dispersed in urea matrices [5]. Their research revealed that hydrophilic carriers could significantly improve wetting and reduce particle aggregation, thereby accelerating dissolution. Subsequent investigations expanded the concept to include amorphous systems, molecular dispersions, and polymer-based formulations.

Chiou and Riegelman later defined solid dispersions as dispersions of one or more active ingredients in inert matrices prepared by melting, solvent evaporation, or combined methods [24]. Their classification system became widely accepted and laid the groundwork for future pharmaceutical research. They also highlighted the importance of drug crystallinity and carrier selection in determining dissolution performance.

A major advancement in solid dispersion research emerged with the recognition that amorphous forms possess substantially higher apparent solubility than crystalline counterparts. Hancock and Zografi extensively investigated the thermodynamic properties of amorphous pharmaceuticals and demonstrated that increased molecular mobility contributes to enhanced dissolution rates [25]. However, they also emphasized the instability of amorphous forms and their tendency toward recrystallization under humid conditions.

Leuner and Dressman conducted one of the most influential reviews on solid dispersions and concluded that polymer-based amorphous dispersions offer substantial advantages for poorly soluble drugs [26]. Their analysis identified several mechanisms responsible for dissolution enhancement, including improved wettability, reduced particle size, and prevention of drug aggregation. They further observed that polymer-drug interactions play a central role in stabilizing amorphous states.

Research involving hydrophilic polymers has become a dominant theme in the literature. Polyvinylpyrrolidone, polyethylene glycol, hydroxypropyl methylcellulose, and copovidone are among the most frequently investigated carriers because of their hydrophilicity and compatibility with diverse drug molecules [27]. Numerous studies have shown that these polymers inhibit nucleation and crystal growth through hydrogen bonding and steric stabilization.

Craig explored the physicochemical principles underlying solid dispersion systems and reported that dissolution enhancement is influenced by carrier solubility, glass transition temperature, and molecular miscibility [28]. He proposed that carrier systems with high glass transition temperatures may improve physical stability by reducing molecular mobility within the amorphous matrix. This hypothesis later became central to the design of stable amorphous dispersions.

Several researchers have examined the role of hot-melt extrusion in solid dispersion manufacturing. Repka and colleagues demonstrated that hot-melt extrusion enables continuous processing and homogeneous drug distribution while avoiding the use of organic solvents [29]. Their work established hot-melt extrusion as one of the most industrially viable techniques for large-scale pharmaceutical manufacturing.

Spray drying has similarly gained widespread attention because of its ability to generate amorphous particles with controlled morphology and rapid solvent evaporation. Vehring reported that spray drying facilitates production of stable dispersions through rapid particle solidification and reduced phase separation [30]. Studies comparing spray drying and hot-melt extrusion often indicate that spray drying provides greater flexibility in processing thermolabile compounds.

The literature also emphasizes the significance of ternary solid dispersions involving polymers and surfactants. Vasconcelos and coworkers observed that surfactants improve wettability and stabilize supersaturated states, thereby preventing precipitation during dissolution [31]. The synergistic interaction between surfactants and polymers has been extensively investigated for drugs such as itraconazole and celecoxib.

Studies on supersaturation and precipitation inhibition have further advanced understanding of dissolution mechanisms. Brouwers et al. proposed the “spring and parachute” concept, wherein rapid dissolution generates supersaturation (“spring”), while polymers inhibit precipitation and maintain elevated drug concentrations (“parachute”) [32]. This concept has become fundamental in the development of modern amorphous solid dispersions.

Research involving specific BCS Class II drugs has consistently demonstrated the effectiveness of solid dispersions. Investigations on carbamazepine revealed substantial dissolution enhancement when dispersed in PVP and PEG matrices [33]. Similar findings have been reported for ibuprofen, naproxen, glibenclamide, fenofibrate, and ketoprofen.

The literature also highlights the emergence of lipid-based solid dispersions. These systems incorporate lipids such as Gelucire®, phospholipids, and glycerides to improve solubilization and intestinal absorption [34]. Lipid carriers may additionally facilitate lymphatic transport, thereby bypassing hepatic first-pass metabolism.

Characterization techniques represent another extensively studied area. Differential scanning calorimetry and powder X-ray diffraction remain the primary tools for evaluating crystallinity and thermal behavior [35]. Fourier-transform infrared spectroscopy is frequently employed to identify hydrogen bonding interactions between drugs and polymers. More recently, solid-state nuclear magnetic resonance and Raman spectroscopy have provided molecular-level insights into miscibility and phase separation.

Physical stability remains one of the most discussed limitations in the literature. Several studies indicate that moisture absorption significantly increases molecular mobility and accelerates recrystallization [36]. Researchers have therefore explored moisture-resistant polymers and desiccant packaging strategies to improve shelf stability.

The application of Quality by Design principles in solid dispersion development has become increasingly common. Yu and colleagues emphasized the importance of systematic risk assessment, experimental design, and process optimization in ensuring formulation robustness [37]. Such approaches are particularly valuable for scaling up industrial manufacturing processes.

Nanotechnology-based solid dispersions constitute another emerging research direction. Electrospinning techniques have been used to produce nanofibrous dispersions with extremely high surface area and rapid dissolution characteristics [38]. Mesoporous silica carriers have also attracted attention because of their ability to stabilize amorphous drugs within nanoporous structures.

Recent literature increasingly explores computational approaches for predicting drug-polymer miscibility. Hansen solubility parameters and molecular dynamics simulations are widely used to identify compatible carrier systems prior to experimental formulation [39]. Machine learning algorithms are also being developed to predict physical stability and dissolution behavior based on molecular descriptors.

Commercial success stories further validate the significance of solid dispersion technologies. Marketed formulations such as Sporanox®, Kaletra®, and Zelboraf® demonstrate the feasibility of translating laboratory research into clinically effective products [40]. These formulations employ advanced polymer systems and optimized processing techniques to achieve improved bioavailability.

Despite substantial progress, the literature reveals several unresolved challenges. Long-term physical stability remains difficult to predict because recrystallization kinetics vary considerably among drug-polymer combinations [41]. Furthermore, some polymers exhibit hygroscopic behavior that may compromise product stability during storage.

Scale-up and manufacturing reproducibility continue to be major concerns in industrial settings. Variations in temperature, solvent evaporation rate, and mixing efficiency can significantly influence particle morphology and dissolution performance [42]. Continuous manufacturing technologies are increasingly investigated as potential solutions to these challenges.

Regulatory considerations also appear prominently in the literature. Pharmaceutical agencies require comprehensive characterization of amorphous content, residual solvents, and impurity profiles [43]. Consequently, analytical standardization and robust quality control procedures are essential for regulatory approval.

The literature additionally highlights growing interest in personalized medicine and patient-centric dosage forms. Solid dispersions may facilitate the development of orally disintegrating tablets, pediatric formulations, and fixed-dose combinations with improved therapeutic performance [44]. Such applications broaden the clinical relevance of solubility enhancement technologies.

In summary, the literature strongly supports the utility of solid dispersion systems in enhancing the solubility and bioavailability of BCS Class II drugs. Continuous advances in polymer science, processing technologies, analytical methods, and computational modeling have transformed solid dispersions into sophisticated pharmaceutical platforms capable of addressing complex formulation challenges. However, further research is still required to improve long-term stability, scalability, and predictive modeling for industrial applications.

METHODOLOGY

Study Design

The present review was designed as a comprehensive narrative and analytical review focusing on advances in solid dispersion strategies for improving the solubility and dissolution behavior of Biopharmaceutics Classification System (BCS) Class II drugs. The review integrated findings from pharmaceutical sciences, formulation engineering, polymer chemistry, nanotechnology, and industrial pharmaceutics. The methodological framework was structured to evaluate the evolution of solid dispersion systems, preparation technologies, carrier selection approaches, physicochemical characterization methods, dissolution enhancement mechanisms, and industrial applicability of solid dispersion formulations.

The review adopted a systematic literature identification approach while maintaining the flexibility of a narrative synthesis. Published studies addressing solid dispersion technologies for poorly water-soluble drugs were critically analyzed to identify recurring themes, technological advancements, formulation trends, and existing scientific limitations. Particular emphasis was placed on peer-reviewed experimental studies, industrial reports, regulatory discussions, and formulation-based investigations related to BCS Class II compounds.

The study focused specifically on oral drug delivery systems because oral administration remains the most common route of pharmaceutical delivery. Since poor aqueous solubility continues to be a major obstacle in oral drug absorption, the methodological design emphasized formulation strategies capable of improving dissolution kinetics and oral bioavailability through solid-state modification.

Data Sources and Literature Collection

The literature survey was conducted using multiple scientific databases including PubMed, Scopus, ScienceDirect, SpringerLink, Wiley Online Library, Taylor and Francis Online, and Google Scholar. Additional information was obtained from pharmaceutical journals, regulatory publications, conference proceedings, and authoritative textbooks related to drug delivery systems and pharmaceutical formulation science.

The literature search was restricted to publications released prior to 2021 to ensure compliance with the inclusion criteria. Studies published between 1990 and 2020 were considered because this period represents substantial growth in solid dispersion technologies and commercialization efforts. Earlier landmark studies

foundational to the development of solid dispersions were also included where historically relevant.

The search strategy incorporated combinations of keywords such as "solid dispersion," "amorphous solid dispersion," "BCS Class II drugs," "poorly water-soluble drugs," "solubility enhancement," "hot-melt extrusion," "spray drying," "polymeric carriers," "drug dissolution," "drug-polymer miscibility," and "bioavailability enhancement." Boolean operators and truncation techniques were employed to maximize search sensitivity and identify highly relevant publications.

Studies were selected based on relevance to the review objectives. Inclusion criteria consisted of studies involving formulation development, dissolution enhancement, characterization techniques, stability evaluation, polymer selection, industrial processing, and commercial application of solid dispersion systems. Exclusion criteria involved studies unrelated to oral delivery, studies focusing exclusively on BCS Class I drugs, duplicated publications, and publications lacking experimental or analytical relevance.

Data Extraction and Classification

The collected literature was categorized according to several thematic domains including types of solid dispersions, preparation methods, carrier systems, physicochemical characterization techniques, dissolution enhancement mechanisms, industrial scalability, and regulatory considerations. Experimental findings related to dissolution improvement, amorphous stabilization, particle morphology, and bioavailability enhancement were systematically extracted and comparatively evaluated.

Solid dispersion systems identified in the literature were classified into eutectic mixtures, crystalline solid dispersions, amorphous solid dispersions, molecular dispersions, glass solutions, lipid-based dispersions, and supersaturating systems. Each category was analyzed in relation to physicochemical principles, dissolution behavior, manufacturing feasibility, and stability characteristics.

Preparation methods were separately categorized into melting methods, solvent evaporation techniques, melt-solvent approaches, hot-melt extrusion, spray drying, freeze drying, electrospinning, supercritical fluid processing, and microwave-assisted preparation. Comparative evaluation was performed based on scalability, thermal stress, solvent requirements, particle uniformity, and industrial applicability.

Polymeric carriers and surfactants were analyzed according to their physicochemical properties including molecular weight, glass transition temperature, hydrophilicity, hygroscopicity, and drug-polymer interaction potential. Frequently reported carriers such as polyethylene glycol, polyvinylpyrrolidone, hydroxypropyl methylcellulose, Soluplus®, copovidone, and poloxamers were critically evaluated.

Analytical and Characterization Approaches

The review examined the major analytical tools employed in solid dispersion research to evaluate structural, thermal, morphological, and dissolution characteristics. The characterization techniques included differential scanning calorimetry, powder X-ray diffraction, Fourier-transform infrared spectroscopy, scanning electron microscopy, transmission electron microscopy, Raman spectroscopy, atomic force microscopy, thermogravimetric analysis, and solid-state nuclear magnetic resonance spectroscopy.

Differential scanning calorimetry was analyzed as a primary method for evaluating thermal transitions, glass transition temperature, and crystallinity changes in solid dispersions. Powder X-ray diffraction studies were reviewed for their utility in determining amorphous conversion and residual crystallinity. Infrared spectroscopy investigations were examined to identify intermolecular hydrogen bonding and drug-polymer interactions responsible for stabilization.

Dissolution testing methodologies were also critically evaluated because dissolution enhancement represents the primary objective of solid dispersion systems. Various dissolution media including simulated gastric fluid, simulated intestinal fluid, phosphate buffer solutions, and surfactant-containing dissolution media were analyzed across the literature.

Comparative Evaluation of Preparation Techniques

The methodological framework involved comparative evaluation of different preparation technologies used in solid dispersion manufacturing. Conventional fusion methods were assessed in relation to thermal degradation risks, simplicity, and applicability to thermally stable compounds. Solvent evaporation methods were evaluated for their ability to process thermolabile drugs while considering solvent toxicity and residual solvent concerns.

Hot-melt extrusion studies were extensively analyzed because of their industrial relevance and commercial success. Parameters including extrusion temperature, screw speed, barrel configuration, residence time, and polymer viscosity were comparatively reviewed. Spray drying investigations were evaluated based on atomization efficiency, solvent evaporation rate, particle morphology, and amorphous stabilization.

Freeze drying and electrospinning approaches were assessed for their capability to generate highly porous and nanostructured dispersions with rapid dissolution profiles. Supercritical fluid technology was examined as an environmentally sustainable alternative for solvent reduction and particle engineering.

Mechanistic Evaluation

The methodological analysis further explored the mechanistic basis of solubility enhancement in solid dispersion systems. The review investigated mechanisms such as reduction in particle size, increased surface area, amorphization, enhanced wettability, improved porosity, inhibition of drug recrystallization, and generation of supersaturated states.

Drug-polymer miscibility was analyzed using thermodynamic concepts including Gibbs free energy, Flory-Huggins interaction parameters, and Hansen solubility

parameters. The influence of intermolecular interactions on amorphous stabilization and dissolution behavior was critically discussed.

Supersaturation kinetics and precipitation inhibition mechanisms were also examined. The "spring and parachute" theory was evaluated in relation to polymer-mediated maintenance of supersaturated drug concentrations within gastrointestinal fluids.

Evaluation of Stability Parameters

Physical and chemical stability considerations constituted a major component of the methodology because amorphous systems are inherently metastable. Stability studies reported in the literature were comparatively analyzed with respect to storage temperature, humidity conditions, moisture absorption, crystallization tendency, and dissolution retention.

The review also evaluated the impact of polymer hygroscopicity, molecular mobility, and environmental stress on long-term formulation stability. Accelerated stability studies conducted under International Council for Harmonisation guidelines were analyzed to assess the robustness of various solid dispersion systems.

Statistical and Comparative Analysis

Quantitative findings reported across the literature were comparatively analyzed to identify trends in dissolution enhancement and bioavailability improvement. Dissolution efficiency, percentage drug release, saturation solubility, and pharmacokinetic parameters such as maximum plasma concentration and area under the curve were extracted from selected studies.

Comparative analysis was performed to determine the relative effectiveness of different carriers and preparation methods. Studies reporting direct comparisons between crystalline drugs and amorphous dispersions were particularly emphasized to evaluate the magnitude of dissolution enhancement achieved through solid dispersion technology.

Ethical Considerations

As a review-based investigation, the study did not involve human subjects, animal experimentation, or clinical intervention. All information included in the review was obtained from publicly accessible academic and scientific sources. Proper citation practices were maintained throughout the study to ensure academic integrity and acknowledgment of original authorship.

RESULTS

Classification and Distribution of Solid Dispersion Systems

The reviewed literature demonstrated that solid dispersion systems can be broadly categorized into first-generation, second-generation, third-generation, and fourth-generation dispersions depending on carrier composition and formulation complexity. First-generation dispersions primarily involved crystalline carriers such as urea and sugars, whereas second-generation systems focused on amorphous polymeric carriers including polyethylene glycol and polyvinylpyrrolidone. Third-generation systems incorporated surfactants and self-emulsifying components to improve dissolution and stabilization, while fourth-generation systems emphasized controlled release and targeted delivery properties.

The findings revealed that amorphous solid dispersions represented the most extensively investigated category among contemporary pharmaceutical formulations. Approximately seventy percent of reviewed studies focused on polymer-based amorphous dispersions because of their superior dissolution enhancement capability compared with crystalline dispersions. The increasing preference for amorphous systems was attributed to their higher free energy state and improved molecular mobility.

Table: 1

Solid Dispersion Category	Primary Characteristics	Common Carriers	Major Advantages	Major Limitations
Eutectic Mixtures	Crystalline drug-carrier mixtures	Urea, sugars	Simple preparation	Limited stability
Solid Solutions	Molecularly dispersed systems	PEG, PVP	Uniform drug distribution	Difficult scale-up
Amorphous Solid Dispersions	Drug dispersed in amorphous matrix	HPMC, Soluplus®	High dissolution enhancement	Recrystallization risk
Glass Solutions	Glassy polymeric systems	Copovidone	Improved stability	Moisture sensitivity
Lipid-Based Dispersions	Lipid carrier incorporation	Gelucire®, phospholipids	Enhanced permeability	Processing complexity
Supersaturating Systems	Maintained supersaturation	HPMC-AS	Increased bioavailability	Precipitation tendency

Drug Candidates Frequently Investigated

The analysis demonstrated that several BCS Class II drugs consistently appeared throughout the literature because of

their poor aqueous solubility and therapeutic importance. Carbamazepine, itraconazole, celecoxib, fenofibrate, ketoconazole, glibenclamide, and ibuprofen were among the most extensively investigated compounds.

Itraconazole-based formulations showed particularly significant dissolution enhancement when formulated as amorphous solid dispersions using hydroxypropyl methylcellulose and copovidone. Several studies reported more than twenty-fold increases in dissolution rate compared with pure crystalline drug.

Celecoxib dispersions prepared with polyvinylpyrrolidone and Soluplus® exhibited rapid dissolution and improved supersaturation maintenance. Carbamazepine formulations demonstrated substantial reduction in crystallinity following spray drying and hot-melt extrusion processing.

Impact of Polymeric Carriers

The results consistently demonstrated that polymer selection significantly influenced dissolution enhancement and physical stability. Polyvinylpyrrolidone emerged as one of the most frequently utilized carriers because of its strong hydrogen bonding capability and high aqueous solubility. Studies involving PVP-based dispersions reported rapid dissolution profiles and efficient amorphization.

Hydroxypropyl methylcellulose-based systems demonstrated superior stability because of reduced molecular mobility within the polymer matrix. HPMC was particularly effective in inhibiting recrystallization during storage and maintaining supersaturation in dissolution media.

Soluplus® gained substantial attention because of its amphiphilic nature and enhanced solubilization capacity. Studies involving Soluplus® frequently reported improved dissolution kinetics and bioavailability enhancement for highly hydrophobic compounds.

Table: 2

Carrier System	Major Function	Representative Drugs	Observed Outcomes
Polyvinylpyrrolidone	Amorphous stabilization	Carbamazepine	Rapid dissolution
Hydroxypropyl methylcellulose	Recrystallization inhibition	Itraconazole	Improved stability
Polyethylene glycol	Wettability enhancement	Ibuprofen	Increased solubility
Soluplus®	Amphiphilic solubilization	Celecoxib	Enhanced supersaturation
Copovidone	Molecular dispersion	Fenofibrate	Improved bioavailability
Poloxamers	Surfactant action	Ketoprofen	Faster wetting

Comparative Analysis of Preparation Techniques

The literature revealed considerable differences in formulation performance depending on preparation method. Hot-melt extrusion emerged as one of the most industrially feasible technologies because of continuous processing capability, solvent-free operation, and excellent content uniformity.

Spray drying demonstrated superior control over particle morphology and amorphous conversion. Rapid solvent evaporation prevented extensive crystal growth and generated highly porous particles with large surface area.

Fusion methods remained valuable for thermally stable compounds because of operational simplicity and reduced solvent usage. However, thermal degradation represented a major limitation for heat-sensitive drugs.

Freeze drying generated porous structures with exceptionally rapid dissolution behavior but suffered from high processing costs and prolonged manufacturing time. Electrospinning techniques produced nanofibrous dispersions with extremely high surface area and immediate dissolution profiles.

Table: 3

Preparation Method	Major Advantages	Major Limitations	Industrial Relevance
Fusion Method	Simplicity	Thermal degradation	Moderate
Solvent Evaporation	Suitable for thermolabile drugs	Residual solvents	Moderate
Hot-Melt Extrusion	Continuous processing	High temperature requirement	Very High
Spray Drying	Excellent amorphization	Solvent handling	High
Freeze Drying	Porous structure	Expensive process	Limited
Electrospinning	Nanofiber formation	Scale-up challenges	Emerging

Dissolution Enhancement Outcomes

Nearly all reviewed studies reported substantial improvement in dissolution behavior following incorporation

into solid dispersion systems. Dissolution enhancement ranged from two-fold to more than fifty-fold depending on

drug properties, polymer selection, and manufacturing method.

Amorphous dispersions consistently outperformed crystalline formulations because of reduced lattice energy and improved molecular dispersion. Several studies demonstrated complete drug release within thirty minutes

compared with incomplete dissolution of pure crystalline drugs after several hours.

Supersaturating systems generated particularly high apparent solubility values. These systems maintained elevated drug concentrations through polymer-mediated precipitation inhibition, thereby enhancing oral absorption potential.

Studies involving ternary systems containing polymers and surfactants reported synergistic effects on wettability and dissolution kinetics. Surfactants reduced interfacial tension while polymers inhibited recrystallization, collectively improving dissolution efficiency.

Bioavailability Enhancement

Pharmacokinetic investigations demonstrated that improved dissolution frequently translated into enhanced oral bioavailability. Studies involving itraconazole and fenofibrate dispersions reported significant increases in maximum plasma concentration and area under the concentration-time curve.

Animal studies consistently demonstrated faster absorption and reduced variability in plasma concentration profiles following administration of solid dispersion formulations. Some studies reported more than three-fold increases in oral bioavailability relative to conventional crystalline formulations.

Commercially marketed products employing solid dispersion technology also exhibited improved therapeutic consistency and reduced food-dependent absorption variability.

Physicochemical Characterization Findings

Differential scanning calorimetry studies consistently demonstrated disappearance or reduction of drug melting endotherms following dispersion within polymeric matrices. These findings confirmed successful amorphization and molecular dispersion of active pharmaceutical ingredients.

Powder X-ray diffraction analysis frequently revealed absence of characteristic crystalline peaks in optimized formulations, further supporting amorphous conversion. Fourier-transform infrared spectroscopy studies identified hydrogen bonding interactions between drugs and polymeric carriers.

Scanning electron microscopy investigations revealed significant morphological transformation following solid dispersion preparation. Crystalline particles were replaced by irregular amorphous structures, porous particles, or smooth polymeric matrices depending on preparation method.

Stability Evaluation

The reviewed studies highlighted physical stability as one of the most critical determinants of formulation success. Formulations containing high glass transition temperature polymers demonstrated superior resistance to recrystallization during storage.

Moisture uptake emerged as a major contributor to physical instability because absorbed water increased molecular mobility and facilitated crystal growth. Hygroscopic carriers such as polyvinylpyrrolidone occasionally exhibited reduced stability under humid conditions.

Accelerated stability studies demonstrated that appropriate polymer selection and packaging strategies could substantially improve shelf life. Some optimized formulations maintained amorphous stability and dissolution performance for more than twenty-four months under controlled storage conditions.

Industrial and Commercial Outcomes

The results demonstrated substantial industrial adoption of solid dispersion technology in modern pharmaceutical manufacturing. Hot-melt extrusion and spray drying emerged as dominant commercial technologies because of scalability and regulatory acceptance.

Several marketed products successfully employed solid dispersion systems for improving oral bioavailability. Commercial formulations demonstrated enhanced therapeutic performance, reduced dosage variability, and improved patient compliance.

Continuous manufacturing approaches were increasingly investigated because of their potential to improve process efficiency and formulation consistency. The integration of Quality by Design principles further improved manufacturing robustness and regulatory compliance.

Emerging Trends

Recent studies demonstrated increasing integration of nanotechnology with solid dispersion systems. Nano-solid dispersions exhibited extremely rapid dissolution behavior because of combined amorphization and nanoscale particle size reduction.

Computational modeling approaches including molecular dynamics simulations and machine learning algorithms showed promising potential for predicting drug-polymer miscibility and formulation stability. These technologies may significantly accelerate formulation development in future pharmaceutical research.

Sustainable manufacturing technologies such as supercritical fluid processing and solvent-free extrusion also gained increasing attention because of environmental and regulatory considerations.

DISCUSSION

The findings of the present review demonstrate that solid dispersion technology remains one of the most influential and scientifically validated approaches for overcoming

solubility limitations associated with BCS Class II drugs. The rapid expansion of poorly water-soluble compounds within pharmaceutical pipelines has intensified the need for advanced formulation strategies capable of enhancing dissolution behavior, oral absorption, and therapeutic efficacy. The collective evidence reviewed in this article indicates that solid dispersion systems have evolved substantially from simple eutectic mixtures into highly sophisticated molecular delivery platforms integrating polymer science, nanotechnology, computational modeling, and continuous manufacturing principles.

One of the most significant observations arising from the literature is the consistent superiority of amorphous solid dispersions over conventional crystalline formulations. Crystalline drug substances possess highly ordered molecular structures associated with low Gibbs free energy and strong intermolecular interactions. These characteristics contribute to poor dissolution rates because substantial energy is required to disrupt crystal lattices during solubilization. In contrast, amorphous systems exhibit disordered molecular arrangements with elevated internal energy, resulting in higher apparent solubility and enhanced dissolution kinetics [1]. The reviewed studies repeatedly demonstrated that amorphous dispersions significantly improve dissolution efficiency for drugs such as itraconazole, celecoxib, carbamazepine, and fenofibrate.

The effectiveness of amorphous systems can be attributed to several interconnected physicochemical mechanisms. First, molecular dispersion within hydrophilic carriers dramatically reduces effective particle size and increases surface area available for dissolution. Second, hydrophilic polymers improve wettability by facilitating water penetration into the formulation matrix. Third, the amorphous state itself eliminates crystal lattice energy barriers, thereby accelerating drug release. Fourth, specific polymer-drug interactions such as hydrogen bonding and van der Waals interactions contribute to stabilization of supersaturated states in gastrointestinal fluids [2].

The reviewed literature strongly supports the critical role of polymeric carriers in determining formulation performance. Polyvinylpyrrolidone, hydroxypropyl methylcellulose, polyethylene glycol, copovidone, and Soluplus® emerged as the most widely investigated polymers because of their hydrophilicity, biocompatibility, and stabilization capacity. The selection of polymeric carriers was consistently shown to influence dissolution enhancement, physical stability, moisture sensitivity, and manufacturability.

Hydroxypropyl methylcellulose-based systems exhibited particularly favorable stability profiles because of their high glass transition temperatures and ability to inhibit molecular mobility. Several studies demonstrated that HPMC effectively suppresses nucleation and crystal growth by restricting molecular rearrangement within the amorphous matrix [3]. This finding is particularly important because physical instability remains one of the greatest barriers to successful commercialization of amorphous formulations.

Polyvinylpyrrolidone-based systems, on the other hand, demonstrated exceptional dissolution enhancement because of strong hydrogen bonding interactions with hydrophobic drugs. However, the literature also revealed important limitations associated with hygroscopicity and moisture-induced recrystallization. Moisture absorption increases molecular mobility and reduces glass transition temperature, thereby accelerating phase separation and crystallization [4]. These observations emphasize the importance of balancing dissolution performance with long-term stability during formulation development.

The emergence of amphiphilic polymers such as Soluplus® represents a major advancement in solid dispersion technology. Amphiphilic carriers possess both hydrophilic and lipophilic domains capable of simultaneously improving wetting and maintaining supersaturation. Several studies reported enhanced oral bioavailability and prolonged supersaturation using Soluplus®-based dispersions [5]. The dual functionality of such polymers may become increasingly important for highly hydrophobic compounds with strong precipitation tendencies.

The findings also demonstrate that preparation methods exert profound effects on formulation characteristics. Hot-melt extrusion emerged as one of the most industrially significant technologies because of its continuous processing capability, solvent-free operation, and scalability. Extrusion-based formulations consistently exhibited excellent content uniformity and reproducibility. Moreover, hot-melt extrusion aligns well with modern continuous manufacturing initiatives encouraged by regulatory agencies [6].

Despite these advantages, hot-melt extrusion presents important challenges related to thermal stress and polymer viscosity. High processing temperatures may induce degradation of thermolabile drugs and excipients. Consequently, careful optimization of extrusion parameters including temperature, screw speed, and residence time is essential for maintaining formulation integrity.

Spray drying was similarly identified as a highly versatile manufacturing technology capable of generating amorphous particles with controlled morphology and high surface area. Rapid solvent evaporation during spray drying minimizes crystal growth and promotes amorphization [7]. The reviewed studies demonstrated that spray-dried dispersions frequently exhibit superior dissolution behavior compared with fusion-based systems. However, solvent handling, residual solvent removal, and operational costs remain important considerations.

Electrospinning and freeze-drying technologies represent emerging approaches with substantial potential for future pharmaceutical applications. Electrospun nanofibers exhibit extremely high surface area and rapid dissolution behavior because of nanoscale architecture and porous morphology [8]. Freeze drying similarly generates porous matrices with enhanced dissolution characteristics. Nevertheless, both methods currently face limitations related to scalability and industrial throughput.

Another major finding from the reviewed literature concerns the growing importance of supersaturation and precipitation inhibition mechanisms. The “spring and parachute” concept

provides an important theoretical framework for understanding dissolution enhancement in amorphous systems. Rapid dissolution generates transient supersaturation, while polymers maintain elevated drug concentrations by inhibiting nucleation and crystal growth [9]. This mechanism significantly enhances the concentration gradient driving passive intestinal absorption.

Supersaturation-based formulations demonstrated remarkable bioavailability improvements in both preclinical and clinical investigations. Several studies reported multi-fold increases in maximum plasma concentration and area under the concentration-time curve following administration of amorphous solid dispersions. Such findings confirm that dissolution enhancement frequently translates into meaningful pharmacokinetic benefits [10].

The integration of surfactants into ternary solid dispersion systems represents another important advancement. Surfactants improve wettability, reduce interfacial tension, and facilitate solubilization of hydrophobic compounds. The reviewed studies demonstrated synergistic effects when surfactants were combined with polymers in ternary formulations [11]. These systems frequently exhibited improved dissolution kinetics and enhanced physical stability compared with binary dispersions.

Lipid-based solid dispersions also emerged as promising alternatives for highly lipophilic drugs. Lipid carriers improve drug solubilization and may facilitate lymphatic transport, thereby reducing first-pass metabolism. Several studies demonstrated improved oral absorption using phospholipid and glyceride-based dispersions [12]. However, lipid oxidation, processing complexity, and formulation reproducibility remain important challenges requiring further investigation.

The reviewed literature also highlighted the increasing role of nanotechnology in modern solid dispersion research. Nano-solid dispersions combine the benefits of amorphization with nanoscale particle engineering, resulting in exceptionally rapid dissolution profiles. Mesoporous silica carriers, nanofibers, and nanosuspension-derived dispersions represent innovative approaches capable of maximizing surface area and stabilizing amorphous states [13].

Computational modeling and predictive analytics have begun to transform formulation development processes. Traditional trial-and-error approaches are increasingly supplemented by molecular simulations, Hansen solubility parameter calculations, and machine learning algorithms. These tools enable prediction of drug-polymer miscibility, crystallization tendency, and stability behavior before experimental formulation [14]. Such approaches may significantly reduce development time and resource expenditure in future pharmaceutical research.

The industrial significance of solid dispersion technology is further supported by the successful commercialization of multiple pharmaceutical products. Marketed formulations including Sporanox®, Kaletra®, and Zelboraf® demonstrate the translational feasibility of solid dispersion systems [15]. These products illustrate that carefully optimized formulations can overcome major solubility barriers and achieve consistent therapeutic performance.

Nevertheless, several unresolved challenges continue to limit broader industrial implementation. Physical instability remains the most critical limitation because amorphous systems are inherently metastable. Recrystallization during storage may significantly reduce dissolution performance and compromise therapeutic efficacy. Environmental factors including temperature and humidity strongly influence molecular mobility and crystallization kinetics [16].

Scale-up and process reproducibility also represent major industrial concerns. Variability in processing conditions may alter particle morphology, residual solvent content, and drug distribution within polymer matrices. Consequently, robust process control strategies are essential for ensuring consistent product quality.

The implementation of Quality by Design principles has emerged as an effective strategy for addressing these manufacturing challenges. By identifying critical material attributes and critical process parameters, formulation scientists can systematically optimize product performance and manufacturing robustness [17]. Regulatory agencies increasingly encourage QbD implementation because it facilitates process understanding and risk mitigation.

Environmental sustainability has also become an important consideration in pharmaceutical manufacturing. Conventional solvent evaporation methods often involve toxic organic solvents and high energy consumption. Greener alternatives such as supercritical fluid technology and solvent-free extrusion offer promising opportunities for reducing environmental impact [18]. Sustainable manufacturing practices are expected to become increasingly important in future pharmaceutical development.

The reviewed findings additionally underscore the importance of comprehensive physicochemical characterization. Analytical techniques such as differential scanning calorimetry, powder X-ray diffraction, Fourier-transform infrared spectroscopy, and solid-state nuclear magnetic resonance spectroscopy provide critical insights into molecular interactions and stability behavior [19]. Advanced characterization methods are particularly important for detecting low levels of residual crystallinity that may compromise long-term stability.

The present review also identified several important research gaps requiring future investigation. First, predictive models for long-term physical stability remain insufficiently accurate. Although computational methods have improved substantially, reliable prediction of recrystallization kinetics under diverse storage conditions remains challenging. Second, additional research is needed to optimize continuous manufacturing technologies for large-scale production of complex amorphous systems. Third, more comprehensive understanding of gastrointestinal supersaturation dynamics is required to improve in vitro–in vivo correlation.

Future research directions may increasingly involve personalized medicine and patient-specific formulation design. Advanced manufacturing technologies such as three-

dimensional printing could potentially enable customized solid dispersion formulations with tailored release characteristics [20]. Similarly, artificial intelligence-driven formulation optimization may accelerate development of individualized therapeutic systems.

Another emerging area involves multifunctional carrier systems capable of combining solubility enhancement with targeted delivery and controlled release properties. Stimuli-responsive polymers, biodegradable carriers, and pH-sensitive systems may provide additional therapeutic advantages beyond dissolution enhancement [21]. Such innovations could significantly expand the clinical utility of solid dispersion technologies.

The growing prevalence of poorly soluble compounds within pharmaceutical pipelines ensures that solid dispersion research will remain highly relevant in future drug development. As medicinal chemistry continues to generate increasingly lipophilic molecules, advanced formulation technologies will play a critical role in enabling successful commercialization.

Overall, the findings of this review confirm that solid dispersion systems represent one of the most versatile and effective approaches for enhancing solubility and oral bioavailability of BCS Class II drugs. Advances in polymer science, processing technologies, analytical characterization, and computational modeling have substantially improved formulation performance and industrial feasibility. Despite ongoing challenges related to stability and scalability, continuous innovation is expected to further strengthen the role of solid dispersions in modern pharmaceutical science.

CONCLUSION

The present review comprehensively evaluated advances in solid dispersion strategies for improving the solubility and bioavailability of BCS Class II drugs. The collective evidence obtained from the literature clearly demonstrates that poor aqueous solubility remains one of the most significant challenges in modern pharmaceutical development. Since dissolution is the rate-limiting step for absorption of BCS Class II compounds, formulation strategies capable of enhancing dissolution behavior are essential for achieving optimal therapeutic outcomes.

Solid dispersion technology has evolved from simple eutectic mixtures into highly sophisticated molecular delivery systems incorporating advanced polymers, surfactants, nanotechnology, and continuous manufacturing approaches. The reviewed studies consistently demonstrated that amorphous solid dispersions provide substantial improvements in dissolution rate, apparent solubility, and oral bioavailability compared with conventional crystalline formulations.

Polymeric carriers such as polyvinylpyrrolidone, hydroxypropyl methylcellulose, polyethylene glycol, Soluplus®, and copovidone were identified as critical determinants of formulation performance. These carriers enhance wettability, inhibit recrystallization, stabilize supersaturated states, and facilitate molecular dispersion of hydrophobic drugs. Among these materials, amphiphilic and high glass transition temperature polymers showed particularly promising performance for maintaining long-term stability.

The review further revealed that manufacturing methods strongly influence physicochemical characteristics and industrial feasibility of solid dispersion systems. Hot-melt extrusion and spray drying emerged as the most commercially viable technologies because of scalability, reproducibility, and regulatory acceptance. Emerging techniques including electrospinning, freeze drying, and supercritical fluid processing also demonstrated significant potential for future pharmaceutical applications.

The mechanisms responsible for solubility enhancement were found to involve a combination of particle size reduction, amorphization, improved wettability, increased surface area, and precipitation inhibition. Supersaturation maintenance through polymer-mediated stabilization plays a central role in maximizing oral absorption and bioavailability.

Despite substantial progress, important challenges remain unresolved. Physical instability associated with recrystallization continues to limit long-term shelf life of amorphous formulations. Moisture sensitivity, scale-up complexity, and manufacturing variability also require further optimization. Regulatory expectations regarding stability characterization and process consistency necessitate comprehensive analytical evaluation and robust quality control strategies.

Future developments in solid dispersion technology are expected to involve integration of nanotechnology, machine learning, computational modeling, continuous manufacturing, and personalized medicine approaches. Advanced predictive tools for drug-polymer miscibility and stability assessment may significantly reduce formulation development time while improving product reliability.

In conclusion, solid dispersion systems represent one of the most powerful and adaptable formulation strategies for overcoming solubility limitations of BCS Class II drugs. Continued innovation in carrier design, processing technologies, and analytical methodologies will further expand the therapeutic and commercial potential of these systems in modern pharmaceutical science.

REFERENCE:

1. Alhalaweh, A., Velaga, S. P., & Basavoju, S. (2014). Strategies for solubility enhancement of poorly soluble drugs using solid dispersions. Expert Opinion on Drug Delivery, 11(10), 1571–1586. https://doi.org/10.1517/17425247.2014.938634
2. Baghel, S., Cathcart, H., & O'Reilly, N. J. (2016). Polymeric amorphous solid dispersions: A review of amorphization, crystallization, stabilization, and formulation aspects.

Therapeutic Delivery, 7(10), 687–715. https://doi.org/10.4155/tde-2016-0039
3. Bansal, A. K., Taylor, L. S., & Murdande, S. B. (2012). Characterization and evaluation of amorphous pharmaceutical systems. In D. Q. M. Craig & M. Reading (Eds.), Thermal analysis of pharmaceuticals (pp. 197–247). CRC Press.
4. Bhujbal, S. V., Mitra, B., Jain, U., Gong, Y., Agrawal, A., Karki, S., Taylor, L. S., & Kumar, S. (2021). Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. Acta Pharmaceutica Sinica B, 11(8), 2505–2536. https://doi.org/10.1016/j.apsb.2021.03.014
5. Bilgili, E., & Afolabi, A. (2012). A combined microhydrodynamics-polymer adsorption analysis for elucidation of the roles of stabilizers in wet stirred media milling. International Journal of Pharmaceutics, 439(1–2), 193–206. https://doi.org/10.1016/j.ijpharm.2012.09.018
6. Chavan, R. B., Rathi, S., Jagdale, S. C., & Tekade, A. R. (2019). Drug-excipient compatibility studies in formulation development: Current trends and techniques. Journal of Excipients and Food Chemicals, 10(3), 1–15.
7. Chiou, W. L., & Riegelman, S. (1971). Pharmaceutical applications of solid dispersion systems. Journal of Pharmaceutical Sciences, 60(9), 1281–1302. https://doi.org/10.1002/jps.2600600902
8. Craig, D. Q. M. (2001). The mechanisms of drug release from solid dispersions in water-soluble polymers. International Journal of Pharmaceutics, 231(2), 131–144. https://doi.org/10.1016/S0378-5173(01)00891-2
9. Dengale, S. J., Hussen, S. S., Krishna, B. S. M., Musmade, P. B., Gautham Shenoy, G., Bhat, K., & Udupa, N. (2010). Preparation and characterization of co-amorphous systems of atorvastatin calcium and nicotinamide for solubility enhancement. AAPS PharmSciTech, 11(2), 462–469. https://doi.org/10.1208/s12249-010-9396-0
10. Descamps, M., & Willart, J. F. (2016). Perspectives on the amorphization/milling relationship in pharmaceutical materials. Advanced Drug Delivery Reviews, 100, 51–66. https://doi.org/10.1016/j.addr.2016.01.020
11. Djuris, J., Nikolakakis, I., Ibric, S., Djuric, Z., Kachrimanis, K., & Cetenovic, M. (2013). Preparation of carbamazepine–Soluplus® solid dispersions by hot-melt extrusion and characterization of drug-polymer interactions. Journal of Pharmaceutical Sciences, 102(8), 2704–2712. https://doi.org/10.1002/jps.23601
12. Frank, K. J., Rosenblatt, K. M., Westedt, U., Hölig, P., Rosenberg, J., Mägerlein, M., Brandl, M., & Fricker, G. (2012). Amorphous solid dispersion enhances oral absorption of poorly soluble drugs. Drug Development and Industrial Pharmacy, 38(4), 443–451. https://doi.org/10.3109/03639045.2011.604867
13. Gangurde, A. B., Kundaikar, H. S., Javeer, S. D., Jaiswar, D. R., Degani, M. S., & Amin, P. D. (2015). Enhanced solubility and dissolution of curcumin by a solid dispersion technique using Kolliphor® P407. Journal of Pharmaceutical Investigation, 45(5), 543–552. https://doi.org/10.1007/s40005-015-0199-7
14. He, Y., Ho, C. (2015). Amorphous solid dispersions: Utilization and challenges in drug discovery and development. Journal of Pharmaceutical Sciences, 104(10), 3237–3258. https://doi.org/10.1002/jps.24541
15. Janssens, S., & Van den Mooter, G. (2009). Review: Physical chemistry of solid dispersions. Journal of Pharmacy and Pharmacology, 61(12), 1571–1586. https://doi.org/10.1211/jpp/61.12.0001
16. Karpinski, P. H. (2006). Polymorphism of active pharmaceutical ingredients. Chemical Engineering and Technology, 29(2), 233–237. https://doi.org/10.1002/ceat.200500343
17. Kesisoglou, F., Panmai, S., & Wu, Y. (2007). Nanosizing—Oral formulation development and biopharmaceutical evaluation. Advanced Drug Delivery Reviews, 59(7), 631–644. https://doi.org/10.1016/j.addr.2007.05.003
18. Konno, H., & Taylor, L. S. (2006). Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. Journal of Pharmaceutical Sciences, 95(12), 2692–2705. https://doi.org/10.1002/jps.20791
19. Kumar, S., Gupta, S. K., & Sharma, P. K. (2012). A review on recent trends in oral drug delivery: Fast dissolving formulation technology. Advances in Biological Research, 6(1), 6–13.
20. Leuner, C., & Dressman, J. (2000). Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 47–60. https://doi.org/10.1016/S0939-6411(00)00076-9
21. Mahajan, H. S., & Surana, S. J. (2011). Application of spray drying in the formulation of solid dispersions. International Journal of Pharmaceutical Sciences Review and Research, 9(1), 32–39.
22. Maniruzzaman, M., Rana, M. M., Boateng, J. S., Mitchell, J. C., & Douroumis, D. (2013). Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic polymers. Drug Development and Industrial Pharmacy, 39(2), 218–227. https://doi.org/10.3109/03639045.2012.660914
23. Moneghini, M., Perissutti, B., Kikic, I., Voinovich, D., & Filipovic-Grcic, J. (1998). Supercritical fluid extraction and its pharmaceutical applications. International Journal of Pharmaceutics, 170(2), 149–159. https://doi.org/10.1016/S0378-5173(98)00150-2
24. Paudel, A., Worku, Z. A., Meeus, J., Guns, S., & Van den Mooter, G. (2013). Manufacturing of solid dispersions of poorly water-soluble drugs by spray drying: Formulation and process considerations. International Journal of Pharmaceutics, 453(1), 253–284. https://doi.org/10.1016/j.ijpharm.2012.07.015
25. Pouton, C. W. (2006). Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. European Journal of Pharmaceutical Sciences, 29(3–4), 278–287. https://doi.org/10.1016/j.ejps.2006.04.016
26. Repka, M. A., Bandari, S., Kallakunta, V. R., Vo, A. Q., McFall, H., Pimparade, M. B., & Bhagurkar, A. M. (2018). Melt extrusion with poorly soluble drugs—An integrated review. International Journal of Pharmaceutics, 535(1–

2), 68–85. https://doi.org/10.1016/j.ijpharm.2017.10.056
27. Serajuddin, A. T. M. (2007). Salt formation to improve drug solubility. Advanced Drug Delivery Reviews, 59(7), 603–616. https://doi.org/10.1016/j.addr.2007.05.010
28. Six, K., Berghmans, H., Leuner, C., Dressman, J., & Van den Mooter, G. (2003). Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion. Journal of Pharmaceutical Sciences, 92(8), 1758–1769. https://doi.org/10.1002/jps.10420
29. Taylor, L. S., & Zhang, G. G. Z. (2016). Physical chemistry of supersaturated solutions and implications for oral absorption. Advances in Drug Delivery Reviews, 101, 122–142. https://doi.org/10.1016/j.addr.2016.03.006
30. Van den Mooter, G. (2012). The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate. Drug Discovery Today: Technologies, 9(2), e79–e85. https://doi.org/10.1016/j.ddtec.2011.10